Arrow
use cases

Prostate Cancer Prediction with AI Models

Early detection and personalized treatment of prostate cancer.

Problem

Prostate cancer remains a major public health problem, being one of the most prevalent cancers affecting men. This disease originates in the prostate gland and varies considerably in its aggressiveness: some forms progress slowly and may require little or no intervention, while others may progress rapidly and metastasize. Age is a primary risk factor; It frequently affects men over 65 years of age, with a higher incidence in black men, those with a family history, and people with obesity (1). Early-stage prostate cancer may present without symptoms, but more advanced disease can cause urinary difficulties, blood in the urine, erectile dysfunction, and pelvic discomfort (2).

Early detection and treatment are critical, and screening methods such as PSA testing and DRE are critical components of effectively managing the condition. Depending on the stage, treatments may include surgery, radiation, hormone therapy, or chemotherapy (3). Prostate cancer is the second most common cancer in men worldwide, and approximately 1 in 8 men are likely to be diagnosed. during his life (3)(4).

Why it matters

  • Prostate cancer is a major public health issue and one of the most prevalent cancers in men, with varying levels of aggressiveness.
  • Age, race, family history, and obesity are primary risk factors, with early-stage disease often presenting without symptoms but advanced stages causing urinary issues, blood in urine, erectile dysfunction, and pelvic discomfort.
  • Prostate cancer is the second most common cancer in men globally, with about 1 in 8 men likely to be diagnosed in their lifetime; early detection through PSA testing and DRE is crucial for effective management.

Solution

"ProCare AI" is an assistant that streamlines risk assessment and provides up-to-date treatment recommendations, improving efficiency in prostate cancer management.

Discover more and interact with our AI!

Datasources

This assistant's training includes data from the Colombian National Cancer Institute's “Manual for Early Detection of Cancer Protherapy” (5), supplemented by the “Guidelines for the Early Detection of Prostate Cancer” by Carter et al. (6), and the clinical practice guidelines of the Ministry of Health and Social Protection of Colombia (7).

Citations

  1. American Cancer Society. (2022). Cancer Facts & Figures 2022. Atlanta: American Cancer Society.
  2. National Cancer Institute. (n.d.). Prostate Cancer—Patient Version. Retrieved from https://www.cancer.gov/types/prostate
  3. Centers for Disease Control and Prevention. (n.d.). Prostate Cancer Statistics. Retrieved from https://www.cdc.gov/cancer/prostate/statistics/index.htm
  4. Prostate Cancer Foundation. (n.d.). About Prostate Cancer. Retrieved from https://www.pcf.org/about-prostate-cancer
  5. Instituto Nacional de Cancerología. (n.d.). Manual para la Detección Temprana del Cáncer de Próstata. Retrieved from https://www.cancer.gov.co/conozca-sobre-cancer-1/publicaciones/manual-para-deteccion-temprana-del-cancer-1
  6. Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., Penson, D. F., & Zietman, A. L. (2013). Early Detection of Prostate Cancer: AUA Guideline. Journal of Urology, 190(2), 419-426. doi: 10.1016/j.juro.2013.04.119
  7. Ministerio de Salud y Protección Social. (2019, February 25). Guía de práctica clínica (GPC) para la detección temprana, diagnóstico, tratamiento, seguimiento y rehabilitación del cáncer de próstata. Retrieved from https://repositorio.mederi.com.co/handle/123456789/342

Problem

Prostate cancer remains a major public health problem, being one of the most prevalent cancers affecting men. This disease originates in the prostate gland and varies considerably in its aggressiveness: some forms progress slowly and may require little or no intervention, while others may progress rapidly and metastasize. Age is a primary risk factor; It frequently affects men over 65 years of age, with a higher incidence in black men, those with a family history, and people with obesity (1). Early-stage prostate cancer may present without symptoms, but more advanced disease can cause urinary difficulties, blood in the urine, erectile dysfunction, and pelvic discomfort (2).

Early detection and treatment are critical, and screening methods such as PSA testing and DRE are critical components of effectively managing the condition. Depending on the stage, treatments may include surgery, radiation, hormone therapy, or chemotherapy (3). Prostate cancer is the second most common cancer in men worldwide, and approximately 1 in 8 men are likely to be diagnosed. during his life (3)(4).

Problem Size

  • Prostate cancer is a major public health issue and one of the most prevalent cancers in men, with varying levels of aggressiveness.
  • Age, race, family history, and obesity are primary risk factors, with early-stage disease often presenting without symptoms but advanced stages causing urinary issues, blood in urine, erectile dysfunction, and pelvic discomfort.
  • Prostate cancer is the second most common cancer in men globally, with about 1 in 8 men likely to be diagnosed in their lifetime; early detection through PSA testing and DRE is crucial for effective management.

Solution

"ProCare AI" is an assistant that streamlines risk assessment and provides up-to-date treatment recommendations, improving efficiency in prostate cancer management.

Opportunity Cost


Impact


Data Sources

This assistant's training includes data from the Colombian National Cancer Institute's “Manual for Early Detection of Cancer Protherapy” (5), supplemented by the “Guidelines for the Early Detection of Prostate Cancer” by Carter et al. (6), and the clinical practice guidelines of the Ministry of Health and Social Protection of Colombia (7).


References

  1. American Cancer Society. (2022). Cancer Facts & Figures 2022. Atlanta: American Cancer Society.
  2. National Cancer Institute. (n.d.). Prostate Cancer—Patient Version. Retrieved from https://www.cancer.gov/types/prostate
  3. Centers for Disease Control and Prevention. (n.d.). Prostate Cancer Statistics. Retrieved from https://www.cdc.gov/cancer/prostate/statistics/index.htm
  4. Prostate Cancer Foundation. (n.d.). About Prostate Cancer. Retrieved from https://www.pcf.org/about-prostate-cancer
  5. Instituto Nacional de Cancerología. (n.d.). Manual para la Detección Temprana del Cáncer de Próstata. Retrieved from https://www.cancer.gov.co/conozca-sobre-cancer-1/publicaciones/manual-para-deteccion-temprana-del-cancer-1
  6. Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., Penson, D. F., & Zietman, A. L. (2013). Early Detection of Prostate Cancer: AUA Guideline. Journal of Urology, 190(2), 419-426. doi: 10.1016/j.juro.2013.04.119
  7. Ministerio de Salud y Protección Social. (2019, February 25). Guía de práctica clínica (GPC) para la detección temprana, diagnóstico, tratamiento, seguimiento y rehabilitación del cáncer de próstata. Retrieved from https://repositorio.mederi.com.co/handle/123456789/342

Book a Free Consultation

Trusted by the world's top healthcare institutions